Selskabets formål er at foretage salg af parallelimporterede lægemidler i Danmark.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 1.2 mia. | 14.9 mio. | 150.4 mio. | 53.9 mio. | 37 | |
CVR: 26058708
Compared to 406 companies in Engroshandel med medicinalvarer og sygeplejeartikler
Comparison is based on industry median values
Companies in the same industry and area
CVR 36089210
CVR 17153684
CVR 25674030
CVR 45236145
CVR 44825775
Nicki Lund Kristensen joined the board
The financial health of ORIFARM A/S appears to be stable, with a slight decline in revenue and profit from 2023 to 2024. Revenue decreased from 1,575,946,000 DKK in 2023 to 1,223,777,000 DKK in 2024, while profit also fell from 18,874,000 DKK to 14,865,000 DKK. Despite this downturn, the company has maintained a solid equity position of 53,921,000 DKK, indicating a strong foundation. However, the declining profit margins raise concerns about operational efficiency and competitiveness within the pharmaceutical wholesale industry. Overall, ORIFARM A/S remains a significant player, but it must address its profitability challenges to sustain its market position.
AI-generated summary
companydata.dk